The aims of the present study were to assess the safety, tolerability and pharmacokinetics of radavirsen following single ascending doses and multiple doses given as intravenous infusions in healthy adults.
Introduction
Therapeutic interventions for influenza A include adamantanes (amantadine and rimantadine), which target the M2 transmembrane proton channel, and neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, and laninamivir), which inhibit viral budding from infected respiratory epithelial cells by blocking neuraminidase activity.
New forms of treatment for influenza A are needed, based on: (i) the known propensity of this virus to undergo both continuous low-level antigenic drift and less frequent but unpredictable major antigenic shift leading to pandemic disease; (ii) the clear failure of vaccination, even when strains are reasonably matched, to prevent influenza-related illness in a significant proportion of vaccine recipients; and (iii) the increased frequency of resistance to approved forms of therapy for influenza [e. Several decades ago, antisense oligonucleotides were found to inhibit influenza virus replication [1] . Phosphorothioate oligodeoxynucleotides inhibit the replication of influenza A at very low concentrations [2] . A more stable phosphorothioate formulation used in a mouse model led to 45% survival and a 1.5 log reduction in viral titre in the lung when 40 mg kg -1 doses were administered every 12 h [3] . The liposomal formulation of various small interfering RNA compounds was demonstrated to be substantially more potent, with 3 mg kg -1 doses providing for a 0.8-1.8 log reduction in lung viral titre, prolongation of median survival time, and up to 45% survival in lethal challenge models [4] . The peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) was the most effective inhibitor of viral titre, with doses as low as 0.15 mg kg -1 , resulting in a 1.9-2.0 log reduction in lung viral titre and 50% survival in a lethal challenge mouse model [5, 6] . PMOs are synthetic molecules designed to mimic the natural nucleic acid structure. As antisense oligonucleotides, they bind to complementary sequences of RNA by standard nucleic acid base-pairing. PMOs are similar to DNA in structure, in that they have standard nucleic acid bases; however, PMOs have morpholine rings instead of the deoxyribose rings of DNA, and are linked through phosphorodiamidate groups instead of phosphates. Radavirsen (previously AVI-7100) is a PMO containing three positive charges in the form of piperazine residues at defined locations along the backbone (PMOplus®). Unlike classic siRNA or other antisense therapeutic approaches with mechanisms of action that ultimately degrade the target mRNA, radavirsen is designed to recognize and bind to specific mRNA sequences in the matrix segment of influenza A and physically block translation as well as processing of pre-mRNA, by preventing the splicing of M1 and M2 transcripts. These proteins are involved in the complex viral replication, assembly and budding processes that enable the virus to reproduce in a host cell and infect other cells in the body. Inhibition of the M1 and M2 matrix proteins is intended to disrupt the viral life-cycle and stop or slow the spread of the disease to other cells in the body. Radavirsen contains CpG motifs, but does not result in immune activation or immune suppression. The viral genomic sequence bound by radavirsen is highly conserved, suggesting no existing resistance potential. Preclinical data suggest that this mechanism may enable broad-spectrum activity against multiple influenza viruses. Further, radavirsen acts synergistically with neuraminidase inhibitors in animal models of infection.
The present phase I study evaluated the safety, tolerability and pharmacokinetics of radavirsen following single and multiple intravenous infusions in healthy adults.
Methods

Study design
This was a phase I randomized, double-blind, placebocontrolled study. It was conducted in accordance with the applicable regulatory and International Conference on Harmonization -Good Clinical Practice requirements. The study protocol and consent were approved by the National Institute of Allergy and Infectious Diseases Institutional Review Board (Protocol 13-I-0029; ClinicalTrials.gov Identifier: NCT01747148). Written informed consent was obtained from potential subjects prior to screening.
Subjects were screened up to 28 days prior to dosing. On the first day of dosing (day 0), subjects were assigned sequentially into one of five cohorts, and randomized to receive radavirsen or normal saline placebo. In the single-dose cohorts, vital signs were obtained 15, 30, 60, and 90 min after the start of each 120-min infusion, at the end of the infusion, and approximately 0.5, 1, 2, 4, and 8 h after the end of the infusion. Pharmacokinetic (PK) blood samples were obtained at baseline, at the end of infusion and approximately 1, 2, 4, and 8 h after the end of the infusion. Subjects were then seen on days 1, 2, 4, 10 and 28 for safety and tolerability follow-up visits (with PK samples drawn on days 1, 2 and 4).
For the multi-dose cohort, subjects were dosed once daily on days 0-4. These subjects were monitored for 2 h after all doses (8 h after the first and last dose), with samples for PK analysis drawn preinfusion on days 0-4, and postinfusion at 1, 2, 4 and 8 h on days 1 and 4 only. Subjects were then seen on days 5, 8, 14 and 32 for follow-up safety visits (with PK measurements drawn on days 5 and 8). All new symptoms or abnormal laboratory results were captured as adverse events.
Study treatment
Radavirsen was manufactured by Sarepta Therapeutics (Cambridge, MA, USA), and supplied in 100 mg ml -1 vials.
For subjects randomized to receive radavirsen, the calculated dose of radavirsen was diluted into a 150 ml bag of normal saline. The bag was masked with an opaque cover, and administered to the subjects as a constant-rate infusion over 2 h. 
Study population
Healthy adult male or female subjects aged 18-60 years, with a body mass index (BMI) of 19-32 kg m -2 and a creatinine clearance ≥90 ml min -1 (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula) were eligible for the study. All subjects were required to have normal laboratory parameters at enrolment, and did not use any prescription or over-the-counter medications, with the exception of acetaminophen, vitamins, seasonal allergy medications and/or contraceptive medications. Females of child-bearing potential were enrolled as long as they had a negative pregnancy test at enrolment and used two effective forms of contraception, at least one which was a barrier method.
Analytical methods
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was used for the quantitative determination of radavirsen in human plasma. An automated solid phase extraction method was used to extract plasma samples, and the resulting extracts were analysed using reversed phase LC-MS/MS with an electrospray interface and selected reaction monitoring in the positive ionization mode. This method was validated over the calibration curve range of 5-1000 ng ml -1 with a 1/x 2 weighted quadratic regression.
The within-run and between-run precision ranged from 1.5% to 10.9% relative standard deviation (RSD) and 0.0% to 5.2% RSD, respectively. The within-run accuracy ranged from 85.9% to 105.0% of nominal, and the between-run accuracy from 91.6% to 100.0% of nominal for all quality control (QC) concentrations, including the lower limit of quantification. For samples above 1000 ng ml -1 , study samples were diluted along with QCs (DiQC) in the same batch, to make sure that the samples were properly diluted and that all the DiQCs were within the acceptance criteria. Extraction recoveries for radavirsen were between 46.8% and 47.5%, and long-term matrix storage stability for radavirsen in human plasma was established at À70°C for up to 209 days.
Statistical methods
This study sample size was designed to detect an adverse event with a true rate of 20% with a probability of 0.74 in any given SAD cohort and 0.93 in the MD cohort, while rarer events with a true rate of 1% could be detected with a probability of 0.06 in any SAD cohort and 0.11 in the MD cohort. Continuous data were described using descriptive statistics: number of observations (n), mean (arithmetic), median, standard deviation, minimum and maximum. Frequencies and percentages were used for summarizing categorical data. Missing data were not imputed. Data are summarized by treatment group [pooled placebo and dose level of radavirsen (0.5 mg kg
PK data were analysed via noncompartmental and compartmental analysis (Phoenix WinNonlin v 6.4, Certara, St Louis, MO, USA). Key parameters of interest, including the maximal observed concentration (C max ), apparent elimination rate constant (λ Z ) determined by calculating the absolute value of the slope of the log-linear regression plasma concentration-time plot, the elimination half-life (t 1/2 ) calculated as 0.693/λ Z , and the area under the concentration vs. time curve from time zero to 24 h postdose (AUC 0-24 ) and extrapolated to infinity (AUC 0-∞ ), were calculated using the 'linear-up, log-down' trapezoidal rule. Dose proportionality and accumulation at steady state were assessed by comparison of geometric mean ratios (GMRs) and 90% confidence intervals (CIs) between doses.
Results
Sixty-six unique subjects were screened between April 2013 and August 2015. Of these, 56 subjects were randomized in the six cohorts. One subject enrolled in the single-dose cohort was also enrolled in the multi-dose cohort (as permitted per protocol) after appropriate washout. Of the 11 subjects screened but not randomized, six were ineligible, one subject moved away from the study site, two subjects did not return calls and two subjects were screened but not needed as all cohorts were fully enrolled. One subject in cohort 1 withdrew after day 2 owing to time constraints. Baseline demographic characteristics of the randomized subjects were comparable among all dose groups, including placebo (Table 1) .
Safety
A total of 153 AEs, regardless of relatedness, were reported in the study: 116 for subjects receiving radavirsen and 37 for the subjects receiving placebo, roughly proportional to the 3:1 randomization of participants to active drug vs. placebo. At least one AE occurred in 44 of the 56 subjects: 31/42 (74%) in subjects who received radavirsen, and 13/14 (93%) in subjects receiving placebo. There were no serious AEs and no subjects discontinued the study because of an AE. There were two grade 3 AEs and two grade 4 AEs -two subjects had a grade 3 AE for increased aspartate aminotransferase (AST) and a grade 4 AE for increased creatine phosphokinase, which was temporally associated with vigorous exercise and judged not to be related to the study drug. Of the remaining 149 AEs, 29 were grade 2 and 120 were grade 1.
One subject in cohort 6 on day 3 had an episode of hypotension and hypoglycaemia (captured as AEs) 1 h and 35 min into the infusion. After several minutes, the symptoms and hypotension resolved, and the infusion was resumed and completed without recurrence of similar symptoms.
The most common AEs were headache [15 events in 12 subjects (28.57%) who received radavirsen and four events in four subjects (28.57%) who received placebo] and proteinuria [15 events in 12 subjects (28.57%) who received radavirsen and three events in three subjects (21.42%) who received placebo]. A drug-related AE was defined as any AE with an investigator causality assessment of possible, probable or definite. All drug-related AEs are presented in Table 2 .
In the multi-dose cohort, the rate of transaminase elevations increased slightly: increased AST levels were noted in five events in four subjects (33%) who received radavirsen (one of which was judged not to be related) vs. none in subjects receiving placebo, and increased ALT levels were noted for three events in three subjects (two of which were judged not to be related) who received radavirsen vs. none in subjects receiving placebo (Table 2) . Proteinuria was more common in the multi-dose cohort, being seen in 9/12 subjects (75%) for a total of 10 events. Proteinuria generally began on days 4-5 (range days 2-14), was detected only on 1-3 study days and peaked at a mean of 37 mg ml -1 (Figure 1 ). When adjusted for urine creatinine, this increase in urine protein persisted. A similar increase was seen in urine beta-2 microglobulin. All proteinuria reversed by day 32.
Pharmacokinetics
Analysis of the SAD cohorts demonstrated that radavirsen demonstrated roughly linear and dose-proportional increases in the PK parameters of C max and AUC 0-24 over the range 0.5-8.0 mg kg -1 (Table 3) . SAD data also showed that radavirsen appeared to follow a bi-exponential decline/twocompartmental PK model ( Figure 2) ; however, analysis from the multiple-dose cohort with extended PK sampling from 24-96 h postdose demonstrated that a third compartment is present in the concentration vs. time profile of radavirsen ( Figure 3 ). SAD data indicated an apparent terminal elimination t 1/2 of radavirsen of approximately 3 h (range Table 2 Number of drug-related adverse events (AEs) (and percentage of subjects with the AE) by preferred term and cohort Radavirsen phase I study 2.7-3.4 h), while the t 1/2 calculated from the newly observed third compartment ranged from 47 h to 162 h. While this third compartment represents the true terminal elimination, it is likely not to be clinically relevant, as all concentrations measured after 24 h postdose throughout the study (including those obtained on day 4 of the multiple-dose cohort) were less than 2% of the observed C max , and the median AUC percentage extrapolation from 24 h extrapolated to infinity was 1.3% in the multiple-dose cohort. Furthermore, multiple-dose data demonstrated no accumulation of radavirsen on day 4 of dosing, based on C max and AUC 0-24 (Table 4) . Geometric mean PK parameters using the two-compartmental model were similar in both the SAD and multiple-dose cohorts (Table 5 ). When using dose-normalized C max and AUC 0-24 to compare across dosing cohorts, there were no differences in any PK parameters based on gender or BMI (data not shown).
Discussion
Radavirsen is a novel inhibitor of influenza A which is being developed for the treatment of influenza A. This putative drug candidate was developed within 7 days of acquisition of the 2009 novel swine-origin influenza A virus H1N1 virus RNA sequence (Sarepta Therapeutics, data on file). The targeting of radavirsen only at influenza A, and not influenza B, is less than ideal in the current influenza drug development Figure 1 Urine protein, protein to creatinine ratio, and beta-2 microglobulin over time in the multi-dose cohort by treatment landscape. However, the ability of the platform quickly to generate a new putative drug candidate against an emerging influenza virus makes this class a potentially significant addition to the armamentarium of influenza therapeutics. The results of the present phase I study suggest that, following single doses ranging up to 8 mg kg -1 , and multiple doses at 8 mg kg -1 day -1 for 5 days, radavirsen appears to be safe and well tolerated. Proteinuria, while mild and reversible, was an unexpected finding. The fact that it was accompanied by elevated beta-2 microglobulin suggests that it may represent glomerular injury. In preclinical toxicity studies with Sprague-Dawley (SD) rats treated for 1 week with radavirsen at 240 mg kg -1 day -1 , there was a mildly higher urine gamma-glutamyl transferase (UGGT) : urine creatinine (UCR) ratio (Sarepta Therapeutics, data on file). In a 2-week toxicity study in SD rats receiving a dose of 240 mg kg -1 day -1 , there were minimally higher urine total protein (UTP) : UCR, moderately higher UGGT : UCR and mildly higher urine cystatin C (UCYC) : urine creatinine ratios, suggestive of potential glomerular injury (Sarepta Therapeutics, data on file). In a 2-week monkey toxicity study in which a dose of 12 mg kg -1 day -1 was used, there were mild-tomoderately increased UGGT : UCR ratios, but evaluation of UCYC, UCYC : UCR ratios, UTP concentration and UTP : UCR ratios did not detect any radavirsen-related changes in glomerular function (Sarepta Therapeutics, data on file). Renal toxicities have been described in the preclinical testing of other antisense oligonucleotides [7] . However, in an integrated safety database across multiple preclinical and clinical studies comprising 710 monkeys and 750 human subjects, there was no evidence of class effect renal toxicities [8] . Furthermore, proteinuria was not reported in other human studies in which Table 4 Multiple dosing accumulation test Figure 3 Plasma concentrations of radavirsen (ng ml -1 ) in the multiple-dose cohort (cohort 6) after the first (day 0) and last (day 4) dose. Data are presented as arithmetic mean ± standard deviation Table 5 Geometric mean (CV%) pharmacokinetic parameters from the two-compartmental model of single ascending and multiple-dose cohorts ) had lower mean day 1 viral shedding (0.57 ± 0.49 log 10 copies ml ), lower cumulative AUC viral shedding (2.94 ± 0.86, 7.51 ± 3.09 and 6.14 ± 3.18 log 10 copies*day ml -1 ) and low viral titre on bronchial alveolar lavage on day 7 (0.00 ± 0.00, 1.04 ± 1.49, and 1.14 ± 1.42 log 10 copies ml ), all of which had a P value of <0.05 vs. saline control by Dunnett's multiple comparisons test (Sarepta Therapeutics, data on file). The AUC at 30 mg kg -1 in a ferret is comparable with that achieved with the 8 mg kg -1 dose in humans ( Table 3 ), suggesting that effective levels can be reached in treatment studies. The third compartment observed in the PK analysis was consistent with a long intracellular t 1/2 . Similar results were described in other PMO studies that were analysed using a noncompartmental approach [10, 11] . Plasma concentrations declined in a multi-phasic manner with prolonged terminal elimination phases, particularly at higher doses, suggesting redistribution back into the plasma from a slowly diffusing tissue source (Sarepta Therapeutics, data on file). These PK observations are similar to those reported with other PMO derivatives under study as potential therapeutic or prophylactic interventions for Ebola [11] or Marburg [10] haemorrhagic virus infections.
Conclusion
This is the first demonstration of the safety, tolerability and pharmacokinetics of an antisense oligonucleotide for the treatment of influenza A. The data attained in the present study suggest that radavirsen is safe and well tolerated at relevant, potentially therapeutic exposures. Further clinical evaluation of radavirsen for the treatment of influenza A virus infections is warranted.
